Novel treatment option for obesity



With up to half of a person’s body mass consisting of skeletal muscle, chronic inflammation of those muscles - which include those found in the limbs - can result in significant physical impairment. According to University of Illinois kinesiology and community health professor Kimberly Huey, past research has demonstrated that the antioxidant properties of Vitamin

Full Post: Vitamin E supplementation may reduce inflammation in the brain

A new study in the January 7th issue of Cell Metabolism, a Cell Press publication, helps to explain why obese people and animals fail to respond to leptin, a hormone produced by fat that signals the brain to stop eating.

What’s more, they show that two FDA-approved drugs might restore leptin sensitivity, offering a novel treatment for obesity.

“Most importantly, our study is the first success in sensitizing obese mice on a high-fat diet to leptin,” said Umut Ozcan of Harvard Medical School. “If it works in humans, it could treat obesity.”

When leptin was first discovered some 13 years ago, it led to great excitement in the field, Ozcan said. Studies showed that leptin administered to obese mice that lacked the hormone lost weight. The buzz over leptin’s potential as an obesity therapy soon waned, however, because obese animals and people don’t respond to the hormone. Efforts to find drugs that act as leptin sensitizers over the years have also failed.

However, the underlying reason why obese individuals become leptin resistant in the first place remained open to question. The new study by Ozcan’s team has shed some light on that issue.

Recent studies by him and his colleagues showed that a condition known as endoplasmic reticulum (ER) stress in peripheral organs plays an important role in obesity-induced insulin resistance and type 2 diabetes. Ozcan describes ERs as protein factories within cells. Within those cellular components, molecular chaperones, which serve as the factory workers, facilitate the folding and transport of proteins. When the chaperones can’t keep up, it triggers a stress response known as the unfolded protein response (UPR).

Ozcan suspected that ER stress and the UPR response might also lead to leptin resistance in the brain’s hypothalamus. The hypothalamus is the primary brain region that responds to leptin, sending a signal that curbs appetite. Mice engineered to have reduced ER capacity or increased ER stress throughout their bodies do gain more weight on a high-fat diet, according to earlier studies.

Ozcan now reports that obese mice manipulated to have increased ER stress only in the hypothalamus show less response to leptin. The animals are not only more leptin resistant, but they also grow significantly more obese on a high-fat diet.

The question then became whether the animals could be resensitized by treating them with either of two pre-existing drugs (4-Phenyl Butyric Acid [PBA] and Tauroursodeoxycholic acid [TUDCA]) that act as ER stress reducers. And the answer, they report, is yes.

“It was very exciting,” Ozcan said of the discovery. “Normal mice treated with the drugs dropped some weight and quickly rebounded, but the knockout mice [that were genetically predisposed to ER stress in the brain] continued to lose weight. It shows that ER stress relievers are leptin sensitizers.”

That makes PBA and TUDCA the first leptin sensitizers, Ozcan emphasized.

“A leptin-sensitizing agent has not been previously described despite the long-standing efforts in both academia and industry,” he wrote. “The results presented in this study provide evidence that chemical chaperones, particularly the PBA and TUDCA, can be used as leptin-sensitizing agents. When the high safety profiles of PBA, TUDCA, and leptin are taken into consideration, our results may define a novel treatment option for obesity.”

http://www.cellpress.com/

Link




When an obesity drug called Leptin was first discovered by scientists 13 years ago, experts hoped the appetite-suppressing hormone would be a possible cure for obesity. Leptin failed to realise those expectations and it was discovered that overweight people became unresponsive to Leptin very quickly due to the development of resistance in the brain

Full Post: Fat busting drug Leptin could make a comeback



The discovery more than a decade ago of leptin, an appetite-suppressing hormone secreted by fat tissue, generated headlines and great hopes for an effective treatment for obesity. But hopes dimmed when it was found that obese people are unresponsive to leptin due to development of leptin resistance in the brain. Now, researchers at Children’s Hospital

Full Post: New hope for leptin as a solution to obesity



Obese people who don’t have high cholesterol or diabetes might think they’re healthy - despite the extra pounds. But new Ohio University research suggests that obesity raises levels of the hormone leptin, which can be as big a threat to the cardiovascular system as cholesterol. Tadeusz Malinski and colleagues have published the first study to directly

Full Post: Obesity raises levels of hormone leptin



Once-promising drugs that were abandoned in the fight against breast cancer still could be effective in obese patients, new research suggests. In laboratory tests, hormones produced by fat cells stimulate breast cancer cells to migrate and invade surrounding tissues, scientists at Emory University School of Medicine found. A class of drugs called epithelial growth factor

Full Post: EGFR inhibitors show promise for obesity



Patients with the skin disease psoriasis appear more likely to have higher levels of leptin (a hormone produced by fat cells that may contribute to obesity and other metabolic abnormalities) than persons without psoriasis, according to a report in the December issue of Archives of Dermatology. Psoriasis is an autoimmune disease that results in a

Full Post: Psoriasis sufferers more likely to have higher levels of leptin